

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name: Name:

Ward: NHI:

Enteral liquid peptide formula

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable
and

Severe malabsorption
or Short bowel syndrome
or Intractable diarrhoea
or Biliary atresia
or Cholestatic liver diseases causing malabsorption
or Cystic fibrosis
or Proven fat malabsorption
or Severe intestinal motility disorders causing significant malabsorption
or Intestinal failure
and The patient is currently receiving funded amino acid formula
and The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula

and

A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable
or For step down from intravenous nutrition

Note: A reasonable trial is defined as a 2-4 week trial.

CONTINUATION

Prerequisites (tick boxes where appropriate)

An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken
and

The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: Date: